Mesenchymal Cell News Volume 12.34 | Sep 1 2020

May 12, 2022

MESCN 12.34 | 1 Sep 2020

Mesenchymal Cell News by STEMCELL Technologies

Vol. 12.34 – 1 September, 2020

TOP STORY

Transcriptional
Regulatory Networks of Tumor-Associated Macrophages That Drive Malignancy in Mesenchymal Glioblastoma

Macrophage receptor with collagenous structure^high tumor associated macrophages induced a phenotypic shift towards mesenchymal cellular state of glioma stem cells, promoting both invasive and proliferative activities, as well as therapeutic resistance to irradiation.
[Genome Biology]

Full Article

Culture mesenchymal stem cells, exosome-free

PUBLICATIONSRanked by the impact factor of the journal

IN VITRO

Identification
of Osteogenic Progenitor Cell-Targeted Peptides That Augment Bone Formation

Researchers report a combinational peptide screening strategy for rapid discovery of ligands that not only bound strongly to osteogenic progenitor cells (OPCs) but also stimulated osteogenic cell Akt signaling in those OPCs.
[Nature Communications]

Full Article

A
Specialized Niche in the Pancreatic Microenvironment Promotes Endocrine Differentiation

Using genetic lineage tracing, transcriptome, and functional studies, researchers identified mesenchymal populations with different roles during pancreatic development.
[Developmental Cell]

Full Article

Human
Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients with COVID-19: A Phase I Clinical Trial

Investigators performed a controlled, non-randomized, Phase I clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.
[Signal Transduction and Targeted Therapy]

Full Article

Adipose-Derived
Mesenchymal Stem Cells Promote the Malignant Phenotype of Cervical Cancer

Investigators described for the first time the impact of adipose-derived stem cells over the malignant behavior of cervical cancer cells.
[Scientific Reports]

Full Article

Biochanin
a Induces a Brown-Fat Phenotype via Improvement of Mitochondrial Biogenesis and Activation of AMPK Signaling in Murine C3H10T1/2 Mesenchymal Stem Cells

Scientists investigated the effect of Biochanin A, an O‐methylated isoflavone on the brown‐fat phenotype formation and on the associated thermogenic program including mitochondrial biogenesis and lipolysis in C3H10T1/2 MSCs.
[Phytotherapy Research]

Abstract

IN VIVO

Single
Cell Transcriptomics Identifies a Signaling Network Coordinating Endoderm and Mesoderm Diversification During Foregut Organogenesis

Researchers validated key predictions with mouse genetics showing that differential hedgehog signaling from the epithelium patterns the splanchnic mesoderm into gut tube mesenchyme versus mesenchyme of the liver.
[Nature Communications]

Full Article

A Hierarchically Ordered Compacted Coil Scaffold for Tissue Regeneration

3D coil compacted scaffolds with hierarchically ordered patterns and tunable coil densities created using speed-programmed melt electrospinning writing successfully led to in vitro cell growth in patterns with tunable cell density.
[NPG Asia Materials]

Full Article

Adipose-Derived
Mesenchymal Stromal Cells Promote Corneal Wound Healing by Accelerating the Clearance of Neutrophils in Cornea

Scientists demonstrated that human adipose-derived mesenchymal stromal cells could effectively inhibit neovascularization during ethanol-induced injury in mouse cornea.
[Cell Death & Disease]

Full Article

Virtual Conference Exhibition: Pluripotent Stem Cells

REVIEWS

Review
of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19

The ongoing studies on coronavirus are using MSCs derived from bone marrow or the umbilical cord to demonstrate their feasibility, safety, and tolerability.
[Stem Cell Reviews and Reports]

Full Article

INDUSTRY AND POLICY NEWS

Pluristem
Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial

Pluristem Therapeutics, Inc. announced FDA has cleared the company’s Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19 outside of the Company’s ongoing Phase II COVID-19 study in the US.
[Pluristem Therapeutics, Inc.]

Press Release

FEATURED EVENT

Transcriptional
Regulatory Networks of Tumor-Associated Macrophages That Drive Malignancy in Mesenchymal Glioblastoma

Identification
of Osteogenic Progenitor Cell-Targeted Peptides That Augment Bone Formation

A
Specialized Niche in the Pancreatic Microenvironment Promotes Endocrine Differentiation

Human
Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients with COVID-19: A Phase I Clinical Trial

Adipose-Derived
Mesenchymal Stem Cells Promote the Malignant Phenotype of Cervical Cancer

Biochanin
a Induces a Brown-Fat Phenotype via Improvement of Mitochondrial Biogenesis and Activation of AMPK Signaling in Murine C3H10T1/2 Mesenchymal Stem Cells

Single
Cell Transcriptomics Identifies a Signaling Network Coordinating Endoderm and Mesoderm Diversification During Foregut Organogenesis

A Hierarchically Ordered Compacted Coil Scaffold for Tissue Regeneration

Adipose-Derived
Mesenchymal Stromal Cells Promote Corneal Wound Healing by Accelerating the Clearance of Neutrophils in Cornea

Review
of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19

Pluristem
Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial

NCRI 2020: Virtual Showcase

> See All Events

Junior Research Group Leader Position – Experimental Oncology and Stem Cell Biology

Postdoctoral Research Associate – Translational Cancer

Postdoctoral
Positions – Signal Transduction

Postdoc – Cancer Biology and Cancer Microenvironments

Postdoctoral Scholar – Biomedical Engineering in Regenerative Medicine

> See All Jobs